 |
encorafenib + binimetinib |
|---|---|
| Trade Name | |
| Orphan Indication | Treatment in Stage IIB-IV melanoma positive for the BRAF mutation |
| USA Market Approval | USA |
| USA Designation Date | 2013-11-19 00:00:00 |
| Sponsor | Array BioPharma, Inc.;125 Cambridge Park Drive, Suite 301;Cambridge, Massachusetts, 02140 |
